001     277119
005     20240229155011.0
024 7 _ |a 10.1186/s12916-023-02934-3
|2 doi
024 7 _ |a pmid:37365585
|2 pmid
024 7 _ |a altmetric:150568469
|2 altmetric
037 _ _ |a DKFZ-2023-01284
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Castro-Espin, Carlota
|0 0000-0001-9050-7590
|b 0
245 _ _ |a Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: results from the EPIC cohort study.
260 _ _ |a Heidelberg [u.a.]
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1687869905_19595
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The Mediterranean diet has been associated with lower risk of breast cancer (BC) but evidence from prospective studies on the role of Mediterranean diet on BC survival remains sparse and conflicting. We aimed to investigate whether adherence to Mediterranean diet prior to diagnosis is associated with overall and BC-specific mortality.A total of 13,270 incident breast cancer cases were identified from an initial sample of 318,686 women in 9 countries from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Adherence to Mediterranean diet was estimated through the adapted relative Mediterranean diet (arMED), a 16-point score that includes 8 key components of the Mediterranean diet and excludes alcohol. The degree of adherence to arMED was classified as low (score 0-5), medium (score 6-8), and high (score 9-16). Multivariable Cox proportional hazards models were used to analyze the association between the arMED score and overall mortality, and Fine-Gray competing risks models were applied for BC-specific mortality.After a mean follow-up of 8.6 years from diagnosis, 2340 women died, including 1475 from breast cancer. Among all BC survivors, low compared to medium adherence to arMED score was associated with a 13% higher risk of all-cause mortality (HR 1.13, 95%CI 1.01-1.26). High compared to medium adherence to arMED showed a non-statistically significant association (HR 0.94; 95% CI 0.84-1.05). With no statistically significant departures from linearity, on a continuous scale, a 3-unit increase in the arMED score was associated with an 8% reduced risk of overall mortality (HR3-unit 0.92, 95% CI: 0.87-0.97). This result sustained when restricted to postmenopausal women and was stronger among metastatic BC cases (HR3-unit 0.81, 95% CI: 0.72-0.91).Consuming a Mediterranean diet before BC diagnosis may improve long-term prognosis, particularly after menopause and in cases of metastatic breast cancer. Well-designed dietary interventions are needed to confirm these findings and define specific dietary recommendations.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Breast cancer
|2 Other
650 _ 7 |a Cancer survivors
|2 Other
650 _ 7 |a Dietary patterns
|2 Other
650 _ 7 |a Mediterranean diet
|2 Other
650 _ 7 |a Prospective studies
|2 Other
700 1 _ |a Bonet, Catalina
|b 1
700 1 _ |a Crous-Bou, Marta
|b 2
700 1 _ |a Nadal-Zaragoza, Núria
|b 3
700 1 _ |a Tjønneland, Anne
|b 4
700 1 _ |a Mellemkjær, Lene
|b 5
700 1 _ |a Hajji-Louati, Mariem
|b 6
700 1 _ |a Truong, Thérèse
|b 7
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 8
|u dkfz
700 1 _ |a Le Cornet, Charlotte
|0 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6
|b 9
|u dkfz
700 1 _ |a Schulze, Matthias B
|b 10
700 1 _ |a Jannasch, Franziska
|b 11
700 1 _ |a Masala, Giovanna
|b 12
700 1 _ |a Sieri, Sabina
|b 13
700 1 _ |a Panico, Salvatore
|b 14
700 1 _ |a Di Girolamo, Chiara
|b 15
700 1 _ |a Skeie, Guri
|b 16
700 1 _ |a Borch, Kristin Benjaminsen
|b 17
700 1 _ |a Olsen, Karina Standahl
|b 18
700 1 _ |a Sánchez, Maria-Jose
|b 19
700 1 _ |a Amiano, Pilar
|b 20
700 1 _ |a Chirlaque, María-Dolores
|b 21
700 1 _ |a Guevara, Marcela
|b 22
700 1 _ |a Sund, Malin
|b 23
700 1 _ |a Bodén, Stina
|b 24
700 1 _ |a Gunter, Marc J
|b 25
700 1 _ |a Gonzalez-Gil, Esther M
|b 26
700 1 _ |a Weiderpass, Elisabete
|b 27
700 1 _ |a Aguilera-Buenosvinos, Inmaculada
|b 28
700 1 _ |a Tsilidis, Kostas K
|b 29
700 1 _ |a Heath, Alicia K
|b 30
700 1 _ |a Aune, Dagfinn
|b 31
700 1 _ |a Dossus, Laure
|b 32
700 1 _ |a Agudo, Antonio
|b 33
773 _ _ |a 10.1186/s12916-023-02934-3
|g Vol. 21, no. 1, p. 225
|0 PERI:(DE-600)2131669-7
|n 1
|p 225
|t BMC medicine
|v 21
|y 2023
|x 1741-7015
909 C O |o oai:inrepo02.dkfz.de:277119
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BMC MED : 2022
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:07:15Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:07:15Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2023-05-02T09:07:15Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BMC MED : 2022
|d 2023-10-25
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21